COIOSDeep risk insights through multi-disciplinary research across the globe
gray scale photo of dumbbells
Item confirms Preprint · not peer-reviewed Added

Older adults starting GLP-1 drugs were younger and heavier than other initiators

Among 58,754 adults aged 65 and over with type 2 diabetes, mean BMI at initiation was 33.8 for GLP-1 drugs as compared to 29.7 for SGLT2 inhibitors.

A retrospective cohort compared new initiators of three glucose-lowering therapies among 58,754 adults aged 65 and over with type 2 diabetes, 2018-2026. A BMI of 30 or above was present in 72.1% of GLP-1 initiators, as compared to 41.9% of SGLT2 initiators. Those starting GLP-1 drugs also had less dementia, heart failure and renal disease, while average HbA1c was similar across the three groups.

Why it is interesting: Shows which older patients receive GLP-1 drugs, and which conditions point prescribing towards the alternatives.

Source
medRxiv, 5 October 2026
Paper
Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults
Authors
Brooks JD, Donahue MA, ElHassan A, Tian J, Hernandez-Diaz S, Blacker D et al.
DOI
10.64898/2026.09.29.26364340
Type
Preprint
Design
Retrospective cohort of 58,754 adults aged 65+ with type 2 diabetes in one regional health system, 2018-2026, comparing new initiators of GLP-1RA (n=5,095), SGLT2i (n=5,483) and DPP-4i (n=1,516)
Verdict
Confirms prior evidence
Driver
Adherence and persistence
Driver
Obesity, diabetes and GLP-1

Other drivers in Behavioural science